FGF23 mutants causing familial tumoral calcinosis are differentially processed

Endocrinology

Volumn 146, Issue 9, 2005, Pages 3883-3891

  Larsson, Tobias ^a   Davis, Siobhan I ^a   Garringer, Holly J ^a   Mooney, Sean D ^a   Draman, Mohamad S ^b   Cullen, Michael J ^b   White, Kenneth E ^a  

^a INDIANA UNIVERSITY   (United States)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

FGF23; Fibroblast Growth Factor 23; GALNT3; Hyperphosphatemia; Hypophosphatemia; Mutant; PHEX; SPC; Subtisilin like pro protein convertases; Tumoral calcinosis

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; MUTANT PROTEIN; PHOSPHATE; PROTEINASE; SERINE; TRYPSIN; VITAMIN D; COMPLEMENTARY DNA; FIBROBLAST GROWTH FACTOR;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CHEMICAL ANALYSIS; CONFORMATIONAL TRANSITION; FAMILIAL DISEASE; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; PATHOPHYSIOLOGY; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SECRETION; TEMPERATURE; TUMOR CALCINOSIS; VITAMIN METABOLISM; WILD TYPE; CALCINOSIS; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; FEMALE; GENETICS; GENOTYPE; KIDNEY; MALE; METABOLISM; PEDIGREE; PHENOTYPE; POINT MUTATION; PROTEIN SECONDARY STRUCTURE;

CALCINOSIS; CELL LINE; DNA, COMPLEMENTARY; FEMALE; FIBROBLAST GROWTH FACTORS; GENOTYPE; HUMANS; KIDNEY; MALE; MODELS, MOLECULAR; PEDIGREE; PHENOTYPE; POINT MUTATION; PROTEIN STRUCTURE, SECONDARY; TEMPERATURE;

EID: 23844457598     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2005-0431     Document Type: Article

References (37)

1. 2000 Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. The ADHR Consortium. Nat Genet 26:345-8.
2. Bianchine JW, Stambler AA, Harrison HE 1971 Familial hypophosphatemic rickets showing autosomal dominant inheritance Birth Defects, pp 287-295
3. Econs MJ, McEnery PT 1997 Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 82:674-81.
4. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S 2002 Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957-60.
5. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H 2003 Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656-63.
6. Weber TJ, Liu S, Indridason OS, Quarles LD 2003 Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18:1227-34.
7. Bai XY, Miao D, Goltzman D, Karaplis AC 2003 The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 278:9843-9
8. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98:6500-5.
9. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T 2004 FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429-35
10. Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H, Jonsson KB 2004 Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145:3087-94
11. Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2004 FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 314:409-14.
12. Bai X, Miao D, Li J, Goltzman D, Karaplis AC 2004 Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145:5269-79
13. Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, H JA-P, Lanske B 2004 Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23:421-32
14. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T 2004 Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113:561-8.
15. Inclan A, Leon P, Schaeffer PC, Goldsmith RS, Chausmer AB 1943 Tumoral calcinosis. JAMA 121:490-495
16. Prince MJ, Schaeffer PC, Goldsmith RS, Chausmer AB 1982 Hyperphosphatemic tumoral calcinosis: association with elevation of serum 1,25- dihydroxycholecalciferol concentrations. Ann Intern Med 96:586-91
17. Mitnick PD, Goldfarb S, Slatopolsky E, Lemann J, Jr., Gray RW, Agus ZS 1980 Calcium and phosphate metabolism in tumoral calcinosis. Ann Intern Med 92:482-7
18. Larsson T, Yu X, Davis SI, Draman MS, Mooney SD, Cullen MJ, White KE 2005 A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab 90:2424-7
19. Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B 2005 An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 14:385-90
20. Araya K, Fukumoto S, Backenroth R, Takeuchi Y, Nakayama K, Ito N, Yamazaki Y, Yamashita T, Silver J, Igarashi T 2004 A mutation in FGF-23 gene enhances the processing of FGF-23 protein and causes tumoral calcinosis. J Bone Miner Res 19:S41
21. Li Voon Chong SW, Ah Kion S, Cullen MJ 1999 A report of familial hyperphosphataemia in an Irish family. Ir J Med Sci 168:262-4
22. White KE, Jonsson KB, Carn G, Hampson G, Spector TD, Mannstadt M, Lorenz-Depiereux B, Miyauchi A, Yang IM, Ljunggren O, Meitinger T, Strom TM, Juppner H, Econs MJ 2001 The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 86:497-500.
23. Harmer NJ, Pellegrini L, Chirgadze D, Fernandez-Recio J, Blundell TL 2004 The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity. Biochemistry 43:629-40
24. Pieper U, Eswar N, Braberg H, Madhusudhan MS, Davis FP, Stuart AC, Mirkovic N, Rossi A, Marti-Renom MA, Fiser A, Webb B, Greenblatt D, Huang CC, Ferrin TE, Sali A 2004 MODBASE, a database of annotated comparative protein structure models, and associated resources. Nucleic Acids Res 32:D217-22
25. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ 2001 Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079-86.
26. Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2002 Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143:3179-82.
27. Welch WJ 2004 Role of quality control pathways in human diseases involving protein misfolding. Semin Cell Dev Biol 15:31-8
28. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ 1992 Processing of mutant cystic fibrosis transmembrane conductance regulator is temperaturesensitive. Nature 358:761-4
29. Morello JP, Salahpour A, Laperriere A, Bernier V, Arthus MF, Lonergan M, Petaja-Repo U, Angers S, Morin D, Bichet DG, Bouvier M 2000 Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest 105:887-95
30. Shimada T, Yamazaki Y, Aono Y, Hasegawa H, Hino R, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2003 Neutralization of intrinsic FGF-23 action by antibodies reveal the essential role of FGF-23 in physiological phosphate and vitamin D metabolism. J Bone Miner Res 18:S97
31. Topaz O, Shurman DL, Bergman R, Indelman M, Ratajczak P, Mizrachi M, Khamaysi Z, Behar D, Petronius D, Friedman V, Zelikovic I, Raimer S, Metzker A, Richard G, Sprecher E 2004 Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 36:579-81
32. Ichikawa S, Lyles KW, Econs MJ 2005 A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive. J Clin Endocrinol Metab 90:2420-3
33. Specker BL, Lichtenstein P, Mimouni F, Gormley C, Tsang RC 1986 Calcium-regulating hormones and minerals from birth to 18 months of age: a cross-sectional study. II. Effects of sex, race, age, season, and diet on serum minerals, parathyroid hormone, and calcitonin. Pediatrics 77:891-6
34. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB 2003 Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64:2272-9.
35. Allen H, Whybro A, Barker M 2002 Endocrine response to escalating-dose phosphate supplementation in men: Is FGF-23 phosphatonin? J Bone Miner Res 17:S:159
36. Burnett SM, Gunawardene S, Bringhurst FR, Juppner H, Finkelstein JS 2004 The effects of dietary phosphate on the regulation of FGF-23 in humans. J Bone Miner Res 19:S252
37. Ferrari SL, Bonjour JP, Rizzoli R 2005 Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90:1519-24